Androgen receptor regulation of vitamin D receptor in response of castration-resistant prostate cancer cells to 1α-hydroxyvitamin D5: A calcitriol analog

Genes and Cancer

Volumn 1, Issue 9, 2010, Pages 927-940

  Mooso, Benjamin ^a,b   Madhav, Anisha ^a   Johnson, Sherra ^a,b   Roy, Mohana ^a,b   Moore, Mary E ^a,b   Moy, Christabel ^a   Loredo, Grace A ^a,b   Mehta, Rajendra G ^c   Vaughan, Andrew T M ^a,b   Ghosh, Paramita M ^a,b  

^a VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ILLINOIS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Androgen receptor; Calcitriol; Prostate cancer; Vitamin D receptor; Vitamin D5

Indexed keywords

1ALPHA HYDROXYVITAMIN D5; ANDROGEN; ANDROGEN RECEPTOR; CALCITRIOL; PROHIBITIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL ISOLATION; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG EFFICACY; GENE EXPRESSION; GROWTH INHIBITION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CANCER; TRANSCRIPTION INITIATION;

EID: 79952826853     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601910385450     Document Type: Article

References (56)

1. Edwards J, Bartlett JM. The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: modifications to the androgen receptor. BJU Int. 2005;95:1320-6.
2. Klotz L. Maximal androgen blockade for advanced prostate cancer. Best Pract Res Clin Endocrinol Metab. 2008;22:331-40.
3. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34-45.
4. Petrylak D. Therapeutic options in androgen-independent prostate cancer: building on docetaxel. BJU Int. 2005;96 Suppl 2:41-6.
5. Boehmer A, Anastasiadis AG, Feyerabend S, et al. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience. Anticancer Res. 2005;25:4481-6.
6. Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs. 2010;70:983-1000.
7. Leman ES, Arlotti JA, Dhir R, Getzenberg RH. Vitamin D and androgen regulation of prostatic growth. J Cell Biochem. 2003;90:138-47.
8. Murthy S, Agoulnik IU, Weigel NL. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate. 2005;64:362-72.
9. Zhao XY, Ly LH, Peehl DM, Feldman D. 1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgendependent. Endocrinology. 1997;138:3290-8.
10. Beer TM, Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. Mol Cancer Ther. 2004;3:373-81.
11. Johnson CS, Muindi JR, Hershberger PA, Trump DL. The antitumor efficacy of calcitriol: preclinical studies. Anticancer Res. 2006;26:2543-9.
12. Trump DL, Hershberger PA, Bernardi RJ, et al. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. J Steroid Biochem Mol Biol. 2004;89-90:519-26.
13. Scher HI, Chi KN, De Wit R, et al. Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): results from the phase III ASCENT2 trial. J Clin Oncol. 2010;28:450-9.
14. Mehta RG, Moriarty RM, Mehta RR, et al. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5. J Natl Cancer Inst. 1997;89:212-8.
15. Mehta R, Hawthorne M, Uselding L, Albinescu D, Moriarty R, Christov K. Prevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats by 1alpha-hydroxyvitamin D(5). J Natl Cancer Inst. 2000;92:1836-40.
16. Mehta RG, Hussain EA, Mehta RR, Das Gupta TK. Chemoprevention of mammary carcinogenesis by 1alpha-hydroxyvitamin D5, a synthetic analog of vitamin D. Mutat Res. 2003;523-524:253-64.
17. Agus DB, Cordon-Cardo C, Fox W, et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999;91:1869-76.
18. Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS. Short hairpin RNA knockdown of the androgen receptor attenuates ligandindependent activation and delays tumor progression. Cancer Res. 2006;66:10613-20.
19. Choudhury A, Charo J, Parapuram SK, et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer. 2004;108:71-7.
20. Haag P, Bektic J, Bartsch G, Klocker H, Eder IE. Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol. 2005;96:251-8.
21. Peehl DM, Feldman D. Interaction of nuclear receptor ligands with the vitamin D signaling pathway in prostate cancer. J Steroid Biochem Mol Biol. 2004;92:307-15.
22. Weigel NL. Interactions between vitamin D and androgen receptor signaling in prostate cancer cells. Nutr Rev. 2007;65:S116-7.
23. Ting HJ, Bao BY, Hsu CL, Lee YF. Androgen-receptor coregulators mediate the suppressive effect of androgen signals on vitamin D receptor activity. Endocrine. 2005;26:1-9.
24. Nuell MJ, Stewart DA, Walker L, et al. Prohibitin, an evolutionarily conserved intracellular protein that blocks DNA synthesis in normal fibroblasts and HeLa cells. Mol Cell Biol. 1991;11:1372-81.
25. Wang S, Nath N, Adlam M, Chellappan S. Prohibitin, a potential tumor suppressor, interacts with RB and regulates E2F function. Oncogene. 1999;18:3501-10.
26. Wang S, Fusaro G, Padmanabhan J, Chellappan SP. Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene. 2002;21:8388-96.
27. Joshi B, Ko D, Ordonez-Ercan D, Chellappan SP. A putative coiledcoil domain of prohibitin is sufficient to repress E2F1-mediated transcription and induce apoptosis. Biochem Biophys Res Commun. 2003;312:459-66.
28. Gamble SC, Odontiadis M, Waxman J, et al. Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene. 2004;23:2996-3004.
29. Gamble SC, Chotai D, Odontiadis M, et al. Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene. 2007;26:1757-68.
30. Dai Y, Ngo D, Jacob J, Forman LW, Faller DV. Prohibitin and the SWI/SNF ATPase subunit BRG1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptorregulated genes. Carcinogenesis. 2008;29:1725-33.
31. Dart DA, Spencer-Dene B, Gamble SC, Waxman J, Bevan CL. Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours. Endocr Relat Cancer. 2009;16:1157-69.
32. Peng X, Mehta R, Wang S, Chellappan S, Mehta RG. Prohibitin is a novel target gene of vitamin D involved in its antiproliferative action in breast cancer cells. Cancer Res. 2006;66:7361-9.
33. Peng X, Mehta RG. Differential expression of prohibitin is correlated with dual action of vitamin D as a proliferative and antiproliferative hormone in breast epithelial cells. J Steroid Biochem Mol Biol. 2007;103:446-50.
34. Esquenet M, Swinnen JV, Heyns W, Verhoeven G. Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1alpha,25-dihydroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid, and phenylacetate. Prostate. 1996;28:182-94.
35. Hsieh TY, Ng CY, Mallouh C, Tazaki H, Wu JM. Regulation of growth, PSA/PAP and androgen receptor expression by 1 alpha, 25-dihydroxyvitamin D3 in the androgen-dependent LNCaP cells. Biochem Biophys Res Commun. 1996;223:141-6.
36. Chen L, Siddiqui S, Bose S, et al. Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells. Cancer Res. 2010;70: 5994-6003.
37. Mikhailova M, Wang Y, Bedolla R, Lu XH, Kreisberg JI, Ghosh PM. AKT regulates androgen receptor-dependent growth and PSA expression in prostate cancer. Adv Exp Med Biol. 2008;617:397-405.
38. Hsieh JT, Wu HC, Gleave ME, von Eschenbach AC, Chung LW. Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. Cancer Res. 1993;53: 2852-7.
39. Ghosh PM, Malik SN, Bedolla RG, et al. Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr Relat Cancer. 2005;12:119-34.
40. Wang Y, Kreisberg JI, Bedolla RG, Mikhailova M, deVere White RW, Ghosh PM. A 90 kDa fragment of filamin A promotes Casodexinduced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells. Oncogene. 2007;26: 6061-70.
41. Wang Y, Mikhailova M, Bose S, Pan CX, deVere White RW, Ghosh PM. Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene. 2008;27:7106-17.
42. Shi XB, Xue L, Tepper CG, et al. The oncogenic potential of a prostate cancer-derived androgen receptor mutant. Prostate. 2007;67: 591-602.
43. Beer TM, Ryan CW, Venner PM, et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of highdose calcitriol plus docetaxel with placebo plus docetaxel. Cancer. 2008;112:326-30.
44. Brawer MK. Recent progress in the treatment of advanced prostate cancer with intermittent dose-intense calcitriol (DN-101). Rev Urol. 2007;9:1-8.
45. Ma Y, Yu WD, Kong RX, Trump DL, Johnson CS. Role of nongenomic activation of phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase 1/2 pathways in 1,25D3-mediated apoptosis in squamous cell carcinoma cells. Cancer Res. 2006;66:8131-8.
46. Mehta RG. Stage-specific inhibition of mammary carcinogenesis by 1alpha-hydroxyvitamin D5. Eur J Cancer. 2004;40:2331-7.
47. Sanchez-Martinez R, Zambrano A, Castillo AI, Aranda A. Vitamin D-dependent recruitment of corepressors to vitamin D/retinoid X receptor heterodimers. Mol Cell Biol. 2008;28:3817-29.
48. Urbanucci A, Waltering KK, Suikki HE, Helenius MA, Visakorpi T. Androgen regulation of the androgen receptor coregulators. BMC Cancer. 2008;8:219.
49. Bao BY, Hu YC, Ting HJ, Lee YF. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene. 2004;23:3350-60.
50. Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci U S A. 2001;98:7200-5.
51. Hofman K, Swinnen JV, Verhoeven G, Heyns W. E2F activity is biphasically regulated by androgens in LNCaP cells. Biochem Biophys Res Commun. 2001;283:97-101.
52. Beer TM, Garzotto M, Park B, et al. Effect of calcitriol on prostatespecific antigen in vitro and in humans. Clin Cancer Res. 2006;12: 2812-6.
53. Ghosh PM, Bedolla R, Mikhailova M, Kreisberg JI. RhoA-dependent murine prostate cancer cell proliferation and apoptosis: role of protein kinase Czeta. Cancer Res. 2002;62:2630-6.
54. Ghosh PM, Mikhailova M, Bedolla R, Kreisberg JI. Arginine vasopressin stimulates mesangial cell proliferation by activating the epidermal growth factor receptor. Am J Physiol Renal Physiol. 2001;280:F972-9.
55. Brinkmann AO, Blok LJ, de Ruiter PE, et al. Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol. 1999;69:307-13.
56. Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW. Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res. 2002;62:1496-502.